- Home
- TSHA vs TNGX Comparison
TSHA vs TNGX Comparison
Compare TSHA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TNGX
- Stock Information
- Founded
- TSHA 2019
- TNGX 2014
- Country
- TSHA United States
- TNGX United States
- Employees
- TSHA N/A
- TNGX N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- TNGX Health Care
- Exchange
- TSHA Nasdaq
- TNGX Nasdaq
- Market Cap
- TSHA 1.2B
- TNGX 1.3B
- IPO Year
- TSHA 2020
- TNGX N/A
- Fundamental
- Price
- TSHA $4.87
- TNGX $10.85
- Analyst Decision
- TSHA Strong Buy
- TNGX Strong Buy
- Analyst Count
- TSHA 9
- TNGX 7
- Target Price
- TSHA $10.22
- TNGX $12.00
- AVG Volume (30 Days)
- TSHA 3.9M
- TNGX 3.2M
- Earning Date
- TSHA 11-04-2025
- TNGX 11-04-2025
- Dividend Yield
- TSHA N/A
- TNGX N/A
- EPS Growth
- TSHA N/A
- TNGX N/A
- EPS
- TSHA N/A
- TNGX N/A
- Revenue
- TSHA $6,310,000.00
- TNGX $66,501,000.00
- Revenue This Year
- TSHA N/A
- TNGX $20.41
- Revenue Next Year
- TSHA N/A
- TNGX N/A
- P/E Ratio
- TSHA N/A
- TNGX N/A
- Revenue Growth
- TSHA N/A
- TNGX 53.29
- 52 Week Low
- TSHA $1.05
- TNGX $1.03
- 52 Week High
- TSHA $5.51
- TNGX $11.20
- Technical
- Relative Strength Index (RSI)
- TSHA 62.34
- TNGX 74.92
- Support Level
- TSHA $3.92
- TNGX $9.90
- Resistance Level
- TSHA $4.34
- TNGX $11.20
- Average True Range (ATR)
- TSHA 0.30
- TNGX 0.74
- MACD
- TSHA 0.06
- TNGX 0.32
- Stochastic Oscillator
- TSHA 98.33
- TNGX 91.64
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.